NASDAQ: TRDAEntrada Therapeutics Inc Stock
$13.56+0.31 (+2.34%)
Updated May 2, 2024
TRDA Price
$13.56
Fair Value Price
N/A
Market Cap
$455.63M
52 Week Low
$10.62
52 Week High
$18.44
P/E
-67.8x
P/B
1.88x
P/S
3.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$129.01M
Earnings
-$6.69M
Gross Margin
100%
Operating Margin
9.34%
Profit Margin
-5.2%
Debt to Equity
0.94
Operating Cash Flow
$140M
Beta
0.92
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TRDA Overview
Entrada Therapeutics Incorporated is a biotechnology company developing Endosomal Escape Vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform is the base for a portfolio of oligonucleotide, antibody, and enzyme-based programs.The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne Muscular Dystrophy and Myotonic Dystrophy-Type 1. The company was known as CycloPorters Inc. until 2017. It was incorporated in 2016 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRDA is good value based on its book value relative to its share price (1.88x), compared to the US Biotechnology industry average (5.99x)
P/B vs Industry Valuation
TRDA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TRDA due diligence checks available for Premium users.
Be the first to know about important TRDA news, forecast changes, insider trades & much more!
TRDA News
Valuation
TRDA fair value
Fair Value of TRDA stock based on Discounted Cash Flow (DCF)
Price
$13.56
Fair Value
$0.11
Overvalued by
11,718.69%
TRDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TRDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-67.8x
Industry
7.63x
Market
35.48x
TRDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
5.99x
TRDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRDA's financial health
Profit margin
Revenue
$41.8M
Net Income
-$9.5M
Profit Margin
-22.8%
TRDA's Earnings (EBIT) of $12.06M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$469.2M
Liabilities
$226.8M
Debt to equity
0.94
TRDA's short-term assets ($369.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRDA's short-term assets ($369.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
$19.0M
Financing
$690.0k
TRDA's operating cash flow ($139.80M)... subscribe to Premium to read more.
Debt Coverage Financials
TRDA vs Biotech Stocks
Entrada Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.